Organon and Eli Lilly and Company have broadened their commercial agreement under which the former will be the sole distributor and promoter of the migraine medication Emgality (galcanezumab) in 11 new markets.
The expanded territories are Canada, Colombia, Israel, Kuwait, Mexico, Qatar, Saudi Arabia, South Korea, Taiwan, Turkey and the United Arab Emirates.
Go deeper with GlobalData
The financial terms of the deal include an upfront payment of $22.5m to Lilly, accompanied by additional sales-based milestone payments.
The deal builds on Organon’s existing distribution responsibilities for the asset in Europe since February 2024.
Organon CEO Kevin Ali stated: “The broadening of this agreement is a testament to Organon’s best-in-class commercialisation capabilities, global footprint and deep expertise in women’s health.
“We know that migraine ranks as the leading cause of disability among young women and we’re proud to expand our offering to more women and men around the world living with episodic or chronic migraine.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataA humanised monoclonal antibody, Emgality acts as a calcitonin gene-related peptide antagonist.
It is designed as a preventive treatment for migraines in adults.
In certain markets, it is specifically indicated for patients experiencing at least four migraine days per month.
The medicine is also approved for treating episodic cluster headaches in adults in some regions.
Under the expanded agreement, Organon will assume full distribution and promotional responsibilities for Emgality in the newly added markets.
Lilly will retain its role as the marketing authorisation holder and continue manufacturing the product for sale.
Eli Lilly and Company executive vice-president and Lilly International president Ilya Yuffa stated: “We are thrilled to expand this collaboration agreement with Organon.
“We’re confident in our shared mission to bring this important migraine treatment to more patients around the world.”
The development comes after Eli Lilly concluded the acquisition of Morphic Holding for $3.2bn, aimed at bolstering its inflammatory bowel disease portfolio.
